Neurodegenerative disease management最新文献

{"title":"Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study.","authors":"Melanie M Tidman, Dawn Reid White, Tim A White","doi":"10.1080/17582024.2024.2352394","DOIUrl":"10.1080/17582024.2024.2352394","url":null,"abstract":"<p><p><b>Aim:</b> Evidence suggests low-carbohydrate diets (LCHF) may assist in treating neurodegenerative diseases such as Parkinson's disease (PD); however, gaps exist in the literature.<b>Patients & methods:</b> We conducted a small 24-week pilot study to investigate the effects of an LCHF diet on motor and nonmotor symptoms, health biomarkers, anxiety, and depression in seven people with PD. We also captured patient experiences during the process (quality of life [QoL]).<b>Results:</b> Participants reported improved biomarkers, enhanced cognition, mood, motor and nonmotor symptoms, and reduced pain and anxiety. Participants felt improvements enhanced their QoL.<b>Conclusion:</b> We conclude that an LCHF intervention is safe, feasible, and potentially effective in mitigating the symptoms of this disorder. However, more extensive randomized controlled studies are needed to create generalizable recommendations.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"97-110"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of neuro-feedback on Alzheimer's rehabilitation: a bibliometric analysis.","authors":"Shruti Verma, Aditya Kurdekar","doi":"10.1080/17582024.2024.2435250","DOIUrl":"10.1080/17582024.2024.2435250","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's Disease (AD) is a neurodegenerative disorder with limited treatment options. Neurofeedback, a technique that trains brainwaves, has shown promise in addressing cognitive impairments.</p><p><strong>Objectives: </strong>To conduct a bibliometric analysis to explore the current research on neurofeedback as a treatment for AD.</p><p><strong>Methods: </strong>A systematic literature review was performed based on PRISMA guidelines on 142 papers. Different bibliometric parameters like the author's country, author names, keywords, journal names, and country of citations were analyzed, and a network visualization chart was generated to understand the correlation of Alzheimer-related search terms to neurofeedback.</p><p><strong>Results: </strong>Research is concentrated in Europe and North America, with a significant gap in Asian countries. A growing body of evidence supports the potential benefits of neurofeedback for AD. A strong correlation has been found between neurofeedback and AD-related terms. Clinical trials suggest positive outcomes for neurofeedback in improving cognitive impairments and working memory.</p><p><strong>Conclusion: </strong>Neurofeedback shows promise as a potential treatment for AD. Further research and clinical studies are needed to explore the full potential of neurofeedback for enhancing the quality of life for individuals with AD.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"257-266"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab.","authors":"Carrie M Hersh, Menglan Pang, Deborah M Miller, Marisa P McGinley, Megan Hyland, Tjalf Ziemssen, Robin L Avila","doi":"10.2217/nmt-2023-0047","DOIUrl":"10.2217/nmt-2023-0047","url":null,"abstract":"<p><p><b>Aim:</b> To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. <b>Methods:</b> Patients enrolled in the MS PATHS network who initiated treatment with either natalizumab or ocrelizumab rated the Neuro-QoL domains of physical function, symptoms, emotional health, cognitive function and social ability. <b>Results:</b> Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumab for cognitive function (event time ratio [95% CI]: 0.37 [0.24-0.57]; p < 0.001), sleep disturbance (0.45 [0.28-0.72]; p = 0.001), social role participation (0.37 [0.21-0.66]; p = 0.001) and social role satisfaction (0.5 [0.31-0.8]; p = 0.004). <b>Conclusion:</b> Natalizumab had shorter time to clinically meaningful improvement in cognitive, sleep, and social role Neuro-QoL domains versus ocrelizumab.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"21-33"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing balance using the BESTest in Alzheimer, Huntington and Parkinson disease.","authors":"Lauren E Tueth, Ryan P Duncan, Beth E Crowner, Gammon M Earhart","doi":"10.1080/17582024.2024.2388507","DOIUrl":"10.1080/17582024.2024.2388507","url":null,"abstract":"<p><p><b>Aim:</b> Individuals with Alzheimer disease (AD), Huntington disease (HD) and Parkinson disease (PD) have impaired balance, and comparing these deficits could improve management of neurological diseases.<b>Methods:</b> Scores on the Balance Evaluation Systems Test (BESTest) were compared across three groups, consisting of individuals with AD, HD and PD in early stages of their respective disease.<b>Results:</b> Individuals with PD had significantly higher scores on the BESTest than individuals with AD (95% CI [4.30, 21.37], <i>p</i> < 0.01) or HD (95% CI [6.53, 24.18], <i>p</i> < 0.001). Individuals with AD and HD were not significantly different on the overall BESTest or any of its subsections.<b>Conclusion:</b> AD and HD may have overlapping pathologies resulting in early and similar balance impairments in these groups.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"87-96"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota and multiple sclerosis: a potential diagnostic and prognostic marker?","authors":"Magdalena Zoledziewska, Lorena Lorefice","doi":"10.1080/17582024.2024.2435249","DOIUrl":"10.1080/17582024.2024.2435249","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"189-192"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"People with multiple sclerosis help design a tool to measure physical functioning and how it affects their daily lives: a plain language summary.","authors":"Paul Kamudoni, Dagmar Amtmann, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Pavle Repovic, Kevin N Alschuler, Gloria von Geldern, Annette Wundes, Amy Barrett, Oyebimpe Olayinka-Amao, Christian Henke","doi":"10.1080/17582024.2024.2357002","DOIUrl":"10.1080/17582024.2024.2357002","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary describes how researchers worked with people with multiple sclerosis (MS), neurologists and measurement experts to create an easy-to-use questionnaire to measure the physical function of people with MS. This questionnaire covers topics that are relevant and important to people with MS and their doctors.The ability to do what you want to do, when you want to do it, is one of the most important concerns for people with MS. This questionnaire could help doctors to record and manage how much MS affects people's lives.MS can bring a range of challenging symptoms such as '<b>brain fog</b>', tiredness, and problems with movement and balance. Many of these symptoms can make day-to-day activities, like working, very difficult for people with MS. Doctors currently use examinations like the <b>Expanded Disability Status Scale (EDSS)</b> and the <b>MS Functional Composite (MSFC)</b>, but these do not fully consider what is important to people living with MS. A questionnaire that specifically measures <b>physical functioning</b> of people with MS could help doctors and people with MS to better understand, communicate and manage the physical effects of MS. In this study, people with MS were asked to help create a questionnaire about physical function that reflects topics that are important to them.</p><p><strong>What were the results?: </strong>The PROMIS^®nq physical function - Multiple Sclerosis 15a (the PROMIS^® PF MS questionnaire) was successfully created with the help of people with MS. People with MS thought that the PROMIS^® PF MS questionnaire covered issues important to their physical function. Scores were in line with results of other physical symptom measurement scales like the EDSS.</p><p><strong>What do the results mean?: </strong>The PROMIS^® PF MS questionnaire could be used to meaningfully record physical function among people with MS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"119-125"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological activities of astaxanthin in the treatment of neurodegenerative diseases.","authors":"Alireza Lotfi, Zahra Abroodi, Mozafar Khazaei","doi":"10.1080/17582024.2024.2433932","DOIUrl":"10.1080/17582024.2024.2433932","url":null,"abstract":"<p><strong>Introduction: </strong>Neurodegenerative diseases (NDs) develop with the gradual advancement of neuronal damage and dysfunction in the central nervous system (CNS). These disorders are mostly the outcomes of the improper sedimentation and accumulation of proteins, such as amyloid-β (Aβ), α-synuclein, and prions. Astaxanthin (AST) exists in different types of living organisms and displays antioxidant and anti-inflammatory functions. This review has concentrated on the therapeutic characteristics of AST on NDs.</p><p><strong>Methods: </strong>Data was collected by searching Scopus, PubMed, and Google Scholar databases. Articles selected for this review reported results on the neuroprotective properties of AST on NDs of studies conducted during the years 2000 to 2024.</p><p><strong>Results: </strong>AST decreases soluble Aβ levels by stimulating the Aβ degradation enzyme. It also reduces inflammation in the substantia nigra (SN) by decreasing IBA1 expression, thereby lessening microglia activity. This carotenoid reduces demyelination by increasing the survival of oligodendrocytes cells and increasing the number of their progenitor cells. AST has antioxidant, anti-inflammatory, and anti-apoptotic properties and can play a role in the treatment of many NDs.</p><p><strong>Conclusion: </strong>There is no definitive treatment for some NDs. The use of AST and natural compounds can be an optimal method for preventing and treating NDs with few side effects.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"241-256"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A discussion with Philippe Huot: the challenges of discovering novel therapies for the treatment of Parkinson's disease.","authors":"Philippe Huot","doi":"10.1080/17582024.2024.2389034","DOIUrl":"10.1080/17582024.2024.2389034","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"127-129"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on nonviral, nonbacterial infectious agents toxicity involved in neurodegenerative diseases.","authors":"Mohammad Taheri, Ali Bahrami, Kiana Kimiaei Asadi, Mojdeh Mohammadi, Pejman Molaei, Mehrdad Hashemi, Fatemeh Nouri","doi":"10.2217/nmt-2023-0004","DOIUrl":"10.2217/nmt-2023-0004","url":null,"abstract":"<p><p>Neuronal death, decreased activity or dysfunction of neurotransmitters are some of the pathophysiological reasons for neurodegenerative diseases like Alzheimer's, Parkinson's and multiple sclerosis. Also, there is evidence for the role of infections and infectious agents in neurodegenerative diseases and the effect of some metabolites in microorganisms in the pathophysiology of these diseases. In this study, we intend to evaluate the existing studies on the role of infectious agents and their metabolites on the pathophysiology of neurodegenerative diseases. PubMed, Scopus, Google Scholar and Web of Science search engines were searched. Some infectious agents have been observed in neurodegenerative diseases. Also, isolations of some fungi and microalgae have an improving effect on Parkinson's and Alzheimer's.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"351-369"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139735730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study of once-a-week donepezil transdermal system's bioequivalence to oral donepezil in healthy volunteers: a plain language summary.","authors":"Rene Braeckman, Charles Oh","doi":"10.2217/nmt-2023-0012","DOIUrl":"10.2217/nmt-2023-0012","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;What is this summary about?: &lt;/strong&gt;This is a plain language summary of an article published in the &lt;i&gt;Journal of Alzheimer's Disease&lt;/i&gt;. It describes an adhesive patch placed on the skin's surface, also referred to as a transdermal delivery system (or TDS), that delivers donepezil (called donepezil TDS going forward) through the skin of patients with mild, moderate, and severe dementia of the Alzheimer's type. This summary focuses on how fast and how much of the medication donepezil enters the body through the skin, and how it compares with taking a pill form of donepezil by mouth (oral donepezil). This summary also looks at how much donepezil is circulating through the body with the use of the once-a-week donepezil TDS versus the once-a-day donepezil pill. We show that the same amount of donepezil circulates through the body when donepezil TDS is used once a week as when a participant takes an oral donepezil pill once a day.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Why is this study important?: &lt;/strong&gt;Dementia is a term used to describe a person's decreasing ability to remember, think, or make decisions necessary to successfully complete daily activities. Alzheimer's disease is a disorder that progresses slowly, with the symptoms of dementia getting worse over many years. When viewed under a microscope, the visible features of Alzheimer's disease within the brain are protein deposits called plaques between brain cells and protein strands within brain cells that appear as tangles. One of the many features that cannot be seen with the naked eye in the Alzheimer's brain is the low level of a chemical called acetylcholine that allows certain nerve cells in the brain involved with memory to communicate with one another. Donepezil, a drug that is widely used to treat dementia associated with Alzheimer's disease, increases the amount of acetylcholine in the brain. Donepezil is usually in pill form and taken by mouth. However, one problem with taking oral donepezil is that it can cause stomach or intestinal side effects like diarrhea, nausea, and vomiting. These side effects may be bad enough that people stop taking their medication. In 2022, for the first time, the United States Food and Drug Administration approved a donepezil TDS marketed under the name Adlarity. Donepezil TDS is for use in patients who have mild, moderate, and severe dementia caused by Alzheimer's disease. It is applied once a week to skin on the patient's back, upper buttocks, or thigh. Donepezil TDS allows the drug donepezil to be absorbed into the body directly through the skin, which means that the drug does not go through the digestive system. This means that many stomach and intestinal side effects (the undesirable effects of the drug) can potentially be reduced.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;What were the results?: &lt;/strong&gt;In healthy volunteers, we showed that donepezil TDS allows a similar amount of the drug into the body as the oral donepezil pill. This is done using a type of examination known as ","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"303-313"},"PeriodicalIF":2.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10218394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}